Skip to main content

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US LinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.27
-4.84 (-2.30%)
AAPL  266.18
+1.60 (0.60%)
AMD  196.60
-3.55 (-1.77%)
BAC  51.07
-1.99 (-3.75%)
GOOG  311.69
-3.21 (-1.02%)
META  637.46
-18.20 (-2.78%)
MSFT  384.47
-12.76 (-3.21%)
NVDA  191.55
+1.73 (0.91%)
ORCL  141.31
-6.77 (-4.57%)
TSLA  399.83
-11.99 (-2.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.